DMAA usually refers to 1,3-dimethylamylamine, also called methylhexanamine or geranamine. It was once used as a nasal decongestant drug, but the FDA says no current medical use is recognized.
The ingredient later appeared in pre-workouts and weight-loss products, often alongside caffeine and sometimes under botanical-sounding language such as geranium extract.
The FDA describes DMAA as an amphetamine derivative and says it is not aware of reliable science showing that DMAA naturally occurs in plants. That matters because “plant extract” wording was used to support claims that it belonged in dietary supplements.
It does not belong to the same category as ordinary dietary ingredients such as amino acids, vitamins, or minerals. And despite the similar abbreviation, DMAA is not DMAE; DMAA vs DMAE explains the distinction.
1,3-dimethylamylamine
DMAA, methylhexanamine, geranamine, dimethylamylamine
Nasal-decongestant drug; no recognized current medical use according to FDA
No, according to FDA and federal court decisions
Products containing DMAA and marketed as dietary supplements are unlawful
Do not buy or use DMAA products
Prohibited in competition under anti-doping rules used by USADA
On the DoD prohibited dietary-supplement ingredients list
Can be declared under aliases or found undeclared in tested products
DMAA acts as a strong sympathomimetic stimulant. In practical terms, it can increase vascular tone and blood pressure. Users historically described stronger energy, urgency, focus, and appetite suppression, especially when DMAA was combined with caffeine.
Those subjective effects are not the same thing as proven exercise benefit or safety.
The controlled human evidence is small. In the best-known acute crossover study, ten healthy adults received DMAA, caffeine, or both on different days. Heart rate did not meaningfully change, but systolic and diastolic blood pressure increased, generally more at the higher DMAA condition and most with the caffeine combination.
The lack of a heart-rate increase does not make the response benign. Blood pressure and rate-pressure product still rose.
Evidence is ordered from controlled human data to observational reports. None of it defines a reliable safe supplement dose.
Limitation: Tiny sample, healthy volunteers, short two-hour follow-up, and doses that should not be interpreted as safe-use recommendations.
Limitation: Small sample, only men, finished multi-ingredient product, limited duration, and insufficient power to exclude uncommon serious harm.
Limitation: Case reports cannot isolate DMAA from caffeine, other ingredients, exertion, heat, individual susceptibility, or other circumstances.
Limitation: Uncontrolled case reports establish a temporal association, not a clean single-ingredient causal estimate or safe-dose boundary.
Limitation: Many products contained multiple ingredients and a large share of exposures involved young children, so the data do not describe a controlled adult dose-response relationship.
Limitation: These findings show product and label risk; they do not measure the prevalence across the entire market.
The 10-week study is frequently presented as proof that DMAA is safe when used “as directed.” That conclusion goes beyond the design.
The study involved only 25 healthy men, split between placebo and a finished supplement. It was not large enough to rule out uncommon events, did not represent people with cardiovascular disease or medication use, and did not isolate DMAA from every co-ingredient.
The supplement group also had an average systolic blood-pressure increase of about 6 mmHg even though the between-group result did not reach statistical significance.
“Not statistically significant” can mean the study did not detect a difference. It does not automatically mean two conditions are equivalent or that a substance is safe for a broad population.
The authors themselves called for longer studies, larger samples, and additional safety measures.
Reported effects associated with DMAA-containing products include:
More serious cardiovascular and neurological events have also been reported. Because many products combine DMAA with caffeine and other stimulants, the precise contribution of each ingredient is often uncertain.
After using a stimulant product, chest pain, difficulty breathing, fainting, a seizure, severe confusion, or a sudden severe headache require emergency medical attention. In the United States, consumers and clinicians can report supplement adverse events through FDA MedWatch.
Caffeine can amplify the cardiovascular burden, but removing caffeine does not create proof that DMAA is safe.
In the acute crossover study, DMAA alone still increased blood pressure, with larger effects at the higher tested condition. The combination with caffeine produced the largest average peak changes.
Real-world supplements also complicate the question. Products may contain other stimulants, proprietary blends, inaccurate amounts, or undeclared ingredients. A person may also consume caffeine from coffee, energy drinks, fat burners, or medication without counting it as part of the stack.
The evidence supports avoiding DMAA rather than trying to engineer a “safe” combination around it. For a direct comparison of the evidence and regulatory status, see DMAA vs Caffeine.
No reliable safe dietary-supplement dose has been established.
The numbers used in small studies describe experimental conditions. They are not approval limits, personal recommendations, or proof that lower amounts are safe. Risk can also change with blood pressure, cardiovascular history, medications, other stimulants, dehydration, heat, exertion, and product purity.
Labels from old proprietary blends are especially poor dosing references because they may not disclose the DMAA amount at all.
For those reasons, FitFrek does not publish a DMAA serving guide, tolerance test, cycling schedule, or maximum amount.
The FDA's position is clear: DMAA is not a dietary ingredient, and DMAA-containing products marketed as dietary supplements are illegal.
The enforcement timeline includes warning letters beginning in 2012, administrative detention of Jack3d and OxyElite Pro in 2013, seizure litigation involving another manufacturer, a 2019 appellate decision affirming that DMAA was not a dietary ingredient and not generally recognized as safe, and the Supreme Court's denial of review in 2020.
This does not mean every legal question is identical across possession, import, sale, sport, military service, and every country. The accurate U.S. consumer statement is that DMAA is unlawful as a dietary-supplement ingredient and the FDA advises against buying or using it.
A prohibited supplement ingredient can remain available through online sellers, smoke shops, convenience stores, imported products, old inventory, relabeling, and undeclared adulteration.
The FDA cannot laboratory-test every product before it reaches the market.
Recent examples make the issue current rather than historical:
The exact chemistry of 1,3-DMAA and 1,4-DMAA is not interchangeable, but both examples show why a high-risk product can be inaccurately labeled.
Direct abbreviation
Common abbreviation for 1,3-dimethylamylamine
Common chemical name and anti-doping term
Historical synonym
FDA-listed alias
FDA-listed alias
May indicate a DMAA-related claim; not proof of contents or plant origin
Does not guarantee absence; FDA has found undeclared stimulant ingredients
Ingredient aliases help screen a label, but only laboratory analysis can confirm the actual contents of a specific lot.
The 2026 WADA Prohibited List places 4-methylhexan-2-amine—1,3-dimethylamylamine / 1,3-DMAA / methylhexaneamine—in the specified-stimulant category prohibited in competition. The list also names 1,4-DMAA separately.
The supplement problem is broader than intentionally choosing DMAA. A product can omit a stimulant, use an unfamiliar alias, or contain a related compound instead of the ingredient printed on the label.
USADA emphasizes strict liability: athletes are ultimately responsible for what is in their systems. Third-party certification can reduce supplement risk, but it cannot make a prohibited ingredient permitted.
DMAA appears on the Department of Defense Prohibited Dietary Supplement Ingredients List.
Operation Supplement Safety tells service members to avoid products containing DMAA and other listed stimulants. Health.mil also states that service members may not take supplements with an ingredient from the DoD prohibited list.
This is a separate rule from civilian dietary-supplement law and from sport anti-doping policy. A product being easy to buy does not make it acceptable for military use.
I used DMAA-era pre-workouts beginning around 2010, so I understand why users remember the energy and focus as different from ordinary caffeine products.
That firsthand experience can describe how a product felt to me. It cannot determine purity, dose, cardiovascular response, or safety for another person.
Subjective intensity is not a substitute for blood-pressure data, adverse-event reports, laboratory testing, or regulatory evidence. The updated page keeps those categories separate instead of using a positive workout as proof that the ingredient is safe.
DMAA can raise systolic and diastolic blood pressure
The largest acute changes in the small crossover study occurred with caffeine plus higher-dose DMAA
DMAA is not lawful as a U.S. dietary-supplement ingredient
Declared labels do not always match laboratory findings
No reliable supplement dose or frequency has been established
Small short studies cannot answer this for a broad population
Risk cannot be calculated from age, fitness, or prior tolerance alone
Multi-ingredient case reports cannot assign every event solely to DMAA
The FDA says it is not aware of reliable science showing DMAA naturally occurs in plants.
Sales volume does not reveal unreported events, actual ingredients, individual exposure, or long-term risk. It is not a substitute for adequate controlled safety data.
The study was small and still found an average systolic increase in the supplement group. Failure to reach statistical significance is not proof of equivalence or safety.
Dose and misuse matter, but acute blood-pressure increases occurred in controlled experimental conditions. Product contents and personal susceptibility also matter.
They are different compounds with different regulatory status and evidence. A rough subjective comparison does not make them interchangeable.
FDA laboratory testing has repeatedly found undeclared DMAA or related stimulants.
FDA says DMAA is not a lawful dietary ingredient and advises consumers not to buy or use DMAA products.
The 2026 WADA Prohibited List includes 1,3-DMAA / methylhexaneamine as a specified stimulant prohibited in competition.
DMAA is on the DoD Prohibited Dietary Supplement Ingredients List.
Cardiovascular concerns, interacting medications, or additional stimulant exposure require individualized medical assessment—not a generic internet threshold.
No group has an established safe dietary-supplement dose. This is a risk summary, not an individualized medical assessment.
DMAA has enough evidence of acute cardiovascular effect—and too little evidence of broad long-term safety—to support a safe-use recommendation.
A tiny acute trial showed blood-pressure increases. A small 10-week trial did not establish equivalence or rule out serious harm. Case reports and poison-center data add warning signals but cannot isolate every co-ingredient. Current FDA testing shows that undeclared DMAA-related stimulants still appear in products.
The legal and practical answer in the United States is straightforward: DMAA is not a lawful dietary-supplement ingredient, and the FDA advises consumers not to buy or use it. If the goal is a current training formula rather than a gray-market stimulant, use FitFrek's Safest Pre-Workouts guide as the next step.
